MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics

  • days left to enroll
  • participants needed
  • sponsor
    Korea Otsuka Pharmaceutical Co., Ltd.
Updated on 21 July 2021
psychotic symptoms
typical antipsychotic


Interventional, multicenter, open-label, 20 weeks study

  • To identify efficacy and safety in switching from oral aripiprazole to Abilify Maintena.
  • To identify efficacy and safety in switching from oral atypical antipsychotics other than aripiprazole to Abilify Maintena


We would like to evaluate the efficacy and safety when switching to Abilify Maintena according to the approved indication of Abilify Maintena, for subjects who are taking oral antipsychotic drugs. It is expected that this will serve as a basis for suggesting a successful switching guideline from oral antipsychotics to Abilify Maintena, which can be applicable in clinical practice.

Condition Antipsychotics, Schizophrenia, Schizophrenia and Schizoaffective Disorders, Schizophrenia and Schizoaffective Disorders (Pediatric), Long-Acting Injection, LAI, Aripiprazole, Long-Acting Injection, Long-Acting Injection, Long-Acting Injection, schizophrenia disorders, antipsychotic, neuroleptics, antipsychotic agent, antipsychotic agents, antipsychotic drug, antipsychotic drugs, Long-Acting Injection
Treatment Abilify maintena
Clinical Study IdentifierNCT03376763
SponsorKorea Otsuka Pharmaceutical Co., Ltd.
Last Modified on21 July 2021

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note